The aim of the present work was to develop solid lipid micro particles (SLMs), as dry powders containing quercetin for a direct administration to the lung for asthma therapy. Quercetin microparticles were prepared by o/w emulsification via a phase inversion technique, using tristearin as lipid and phosphatidylcholine as emulsifier. The quercetin SLMs were characterised for morphology, particle size distribution, residual humidity, crystallinity, thermal behaviour and in vitro respirable fraction. Furthermore, the toxicity and the in vitro transport of the SLMs on the air liquid interface model of the Calu-3 cell line was also investigated using a modified Twin –stage impinger apparatus. Results have showed that querectine SLMs can be formulated as dry powder suitable for inhalation drug delivery. These SLMs have been proven to be not toxic at the concentrations investigated and transported with a liner kinetic through the Calu-3 monolayer, possibly via a diffusion mechanism enhanced by the presence of the lipid/emulsifying excipients. Further studies are necessary to elucidate the exact mechanisms.

Quercetin Solid Lipid Microparticles: a flavonoid for inhalation lung delivery

SCALIA, Santo
Primo
;
TROTTA, Valentina;Traini D.
Ultimo
2013

Abstract

The aim of the present work was to develop solid lipid micro particles (SLMs), as dry powders containing quercetin for a direct administration to the lung for asthma therapy. Quercetin microparticles were prepared by o/w emulsification via a phase inversion technique, using tristearin as lipid and phosphatidylcholine as emulsifier. The quercetin SLMs were characterised for morphology, particle size distribution, residual humidity, crystallinity, thermal behaviour and in vitro respirable fraction. Furthermore, the toxicity and the in vitro transport of the SLMs on the air liquid interface model of the Calu-3 cell line was also investigated using a modified Twin –stage impinger apparatus. Results have showed that querectine SLMs can be formulated as dry powder suitable for inhalation drug delivery. These SLMs have been proven to be not toxic at the concentrations investigated and transported with a liner kinetic through the Calu-3 monolayer, possibly via a diffusion mechanism enhanced by the presence of the lipid/emulsifying excipients. Further studies are necessary to elucidate the exact mechanisms.
2013
Scalia, Santo; Haghi, M.; Losi, V.; Trotta, Valentina; Young, P.; Traini, D.
File in questo prodotto:
File Dimensione Formato  
EJPS2013 .pdf

solo gestori archivio

Descrizione: articolo principale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/1814501
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 51
social impact